TRANSCENTA HOLDING - A global Fully Integrated Biotherapeutics Company
Transcenta, biologics, antibody
Employ cutting-edge technology to discover and deliver high quality innovative biologics at affordable price to patients around the world.
We are a group of people with passion and experience for developing innovative medicines to serve patients around the world. We operate globally and focus on biologics, and we have established a fully integrated capability with a Discovery, Translational and Clinical Research Center in Suzhou, a Process and Product Development Center and Manufacturing Facility in Hangzhou, and Clinical Development Centers in Shanghai, Beijing and Princeton, US, and an External Partnering Center in Boston, US.
Co-founder & CEO
Acting Chief Medical Officer
Chief Technology Officer
Chief Operating Officer
SVP, Process Development
SVP, Clinical Development
SVP, Finance & Business Operations
VP Commercial Planning and Business Analysis
Co-founder & Chairman, Transcenta
Co-founder & CEO, Transcenta
Founder & Managing Partner, Lilly Asia Ventures
Managing Director, Temasek
Vice President, Hillhouse Capital
Partner, Sequoia Capital China
Executive Director, Taikang
Advisor, Teng Yue Partners
Transcenta is backed by prominent investors with approximately $237 million, including Lilly Asia Ventures, Temasek, ARCH Venture Partners, Hillhouse Capital, Teng Yue Partners, Taikang, Sequoia Capital China, CRCP, Fortune Capital, Epiphron Capital, KingStar Capital, China Merchants Capital and China Equity Group. We appreciate their trust and support.
SVP Finance Business Operations
Albert has 15 years of experience in the financial field and has worked in the Audit and Trading Consulting department of PWC, providing IPO audits, annual audits, transaction due diligence, post management, transaction integration and other related financial advisory services. Over the past 10 years, he has been responsible for assisting clients to list in mainland China and Hong Kong's capital markets by verifying compliance with the rules of relevant capital market regulation and reporting. In addition, he also participated in a number of M&A consulting projects to assist domestic and foreign clients to carry out due diligence, design trading structure, to ensure smooth transactions, as well as to carry out the integration of the financial sector to improve the clients and the target companies’ financial system and processes. Albert has received his bachelor degree from Sun Yat-sen University and is a member of the CICPA and the ACCA.